Medivation's XTL6001 Accepted for Presentations at EASD 2026 and ASN Kidney Week 2026
According to a company announcement on August 17, Medivation-B (02335) announced that research data on XTL6001, its lead triple MasR/GCGR/GLP-1R agonist, has been accepted for presentations at EASD 2026 and ASN Kidney Week 2026. Two research abstracts on XTL6001 were accepted at the 62nd European
GateNews·08-17 10:46
